比较泮托拉唑、奥美拉唑分别联合生长抑素对急性胰腺炎患者血尿淀粉酶恢复时间、肠黏膜功能及炎症介质的影响

Comparison on the Effects of pantoprazole and omeprazole combined with somatostatin on amyl⁃ase recovery time,intestinal mucosal function and inflammatory mediators in patients with acute pancreatitis

目的探讨泮托拉唑、奥美拉唑分别联合生长抑素对急性胰腺炎患者血尿淀粉酶恢复时间、肠黏膜功能及炎症介质的影响。方法选取我院2019年6月至2021年6月收治的88例急性胰腺炎患者为研究对象,随机分为观察组与对照组,44例观察组患者实施泮托拉唑联合生长抑素治疗,44例对照组患者实施奥美拉唑联合生长抑素治疗。比较治疗后两组患者血淀粉酶及尿淀粉酶恢复时间、肠黏膜功能情况及炎症介质变化情况。结果治疗后观察组患者血淀粉酶、尿淀粉酶恢复时间分别为(2.62±1.24)d、(3.89±1.52)d均短于对照组血淀粉酶(4.78±1.45)d、尿淀粉酶(5.61±1.67)d(P<0.05);治疗后观察组患者腹胀腹痛、肠黏膜功能恢复时间分别为(2.38±1.21)d、(2.59±1.03)d均短于对照组腹胀腹痛(4.32±1.46)d、肠黏膜功能(4.11±1.22)d(P<0.05);治疗后,两组患者炎症介质水平均降低,且观察组患者CRP(41.29±10.84)mg/L、IL⁃6(35.78±4.51)ng/L、IL⁃8(38.75±6.92)ng/L水平均低于对照组CRP(56.45±10.62)mg/L、IL⁃6(44.69±5.46)ng/L、IL⁃8(49.66±6.84)ng/L(P<0.05)。结论泮托拉唑联合生长抑素的临床效果更佳,可以更好的改善患者相关临床症状与肠道功能,控制机体炎性反应,值得临床广泛推广。

Objective To investigate the effects of pantoprazole and omeprazole combined with somatostatin on amylase recovery time,intestinal mucosal function and inflammatory mediators in patients with acute pancreatitis.Methods Eighty⁃eight patients with acute pancreatitis admitted to our hospital from June 2019 to June 2021 were randomly divided into an observation group(n=44)treated with pantoprazole combined with somatostatin and a control group(n=44)treated with omeprazole combined with somatostatin.The recovery time of urinary amylase,intestinal mucosal function and changes of in⁃flammatory mediators after treatment were compared between the two groups.Results After treatment,the recovery time of serum amylase and urine amylase in the observation group was(2.62±1.24)d and(3.89±1.52)d,respectively;the recov⁃ery time of serum amylase and urine amylase in the control group was(4.78±1.45)d and(5.61±1.67)d,respectively,significantly shorter(P<0.05).After treatment,the recovery time of abdominal distension,abdominal pain and intestinal mucosal function in the observation group was(2.38±1.21)d and(2.59±1.03)d,respectively;the abdominal distension,abdominal pain in the control group was(4.32±1.46)d and intestinal mucosal function was(4.11±1.22)d,respectively,significantly shorter(P<0.05).After treatment,the levels of inflammatory mediators decreased in both groups,and the lev⁃els of CRP(41.29±10.84)mg/L,IL⁃6(35.78±4.51)ng/L and IL⁃8(38.75±6.92)ng/L in the observation group were lower than those[(56.45±10.62)mg/L,(44.69±5.46)ng/L and(49.66±6.84)ng/L]in the control group(P<0.05).Conclusion Pantoprazole combined with somatostatin has better clinical effect,can better improve the relevant clinical symptoms and intestinal function of patients,and control the body′s inflammatory response.It is worthy of clinical application.